Integrative Molecular Epidemiology of Neurocognitive Outcomes in Acute Lymphoblastic Leukemia

急性淋巴细胞白血病神经认知结果的综合分子流行病学

• 批准号: 10381514
• 负责人: Austin L Brown
• 金额: $ 14.87万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-04-11 至 2023-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10381514
• 关键词: Acute; Acute Lymphocytic Leukemia; Address; Advisory Committees; Aftercare; Antimetabolites; Area; Attention; Award; Biological Markers; Biological Specimen Banks; Cancer Patient; Cerebrospinal Fluid; Child; Childhood Acute Lymphocytic Leukemia; Chronic; Clinical; Cognition; Complement; Cranial Irradiation; Data; Development; Diagnosis; Diagnostic; Distress; Enrollment; Epidemiology; Equilibrium; Evaluation; Fatigue; Foundations; Functional disorder; Funding; Future; Genetic; Genetic Variation; Genomics; Goals; Grant; Individual; Inherited; Intervention; Investigation; K-Series Research Career Programs; Leukemia Acute Lymphoblastic Chemotherapy; Literature; Malignant Childhood Neoplasm; Malignant Neoplasms; Mental Depression; Mentors; Mentorship; Molecular; Molecular Epidemiology; National Cancer Advisory Board; Nervous System Trauma; Neuraxis; Neurocognitive; Neurocognitive Deficit; Neurologic; Neuropsychology; Outcome; Outcome Study; Pain; Parents; Pathogenicity; Pathway interactions; Patients; Pediatric cohort; Performance; Phase; Phenotype; Population; Predisposition; Psychology; Quality of life; Quantitative Trait Loci; Reporting; Research; Research Methodology; Resources; Risk; Sampling; Short-Term Memory; Sleep; Survival Rate; Survivors; Symptoms; Toxic effect; Training; Treatment Protocols; Treatment-related toxicity; United States National Institutes of Health; Validation; Vulnerable Populations; Writing; acute symptom; adverse outcome; cancer therapy; career; career development; chemotherapy; clinically significant; cohort; data repository; design; experience; genetic variant; genomic biomarker; genomic data; genomic locus; genomic profiles; high risk; improved; information processing; innovation; leukemia treatment; metabolome; metabolomics; new therapeutic target; novel marker; patient subsets; phenotypic data; processing speed; programs; prospective; research and development; response; skills; symptom treatment; targeted delivery; therapeutic target; training opportunity; translational potential; treatment response; treatment strategy

Project Summary/Abstract This K07 Career Development Award proposal details the rigorous training, research, and mentorship program that will provide a foundation for Dr. Brown to launch a successful independent research career. Dr. Brown’s long-term career goal is to establish a productive independent research program, with an emphasis on identifying novel biomarkers and modifiable therapeutic targets to reduce the burden of treatment-related toxicity among pediatric cancer patients. Therefore, the research goal for this proposal is to characterize early phenotypic, metabolomic, and genomic biomarkers of chemotherapy-associated neurocognitive impairment in pediatric acute lymphoblastic leukemia (ALL) patients. Although improved treatment regimens for pediatric ALL have resulted in survival rates exceeding 90%, nearly half of patients experience chronic treatment-related neurocognitive dysfunction. This proposal pursues the hypothesis that central nervous system-directed ALL chemotherapy disrupts the equilibrium of cerebral spinal fluid (CSF) metabolome, manifesting as acute symptom toxicity and long-term neurocognitive dysfunction. Because genetic factors likely control the CSF metabolomic response to therapy, we further hypothesize that integrating genetic and metabolomics data will lead to the discovery of causal genetic pathways. The specific research aims of this proposal will evaluate whether: 1) Symptom toxicity during the post-induction phase of ALL therapy reflects chemotherapy-directed neurologic damage and serves as an early marker of post-treatment neurocognitive performance; 2) ALL chemotherapy induces consistent and recognizable changes to CSF metabolomic pathways involved in normal neurocognitive function and development; and 3) Genetic variation modifies individual susceptibility to neurocognitive impairment. Leveraging two NIH-funded studies with rich phenotype data and biospecimen repositories, this innovative proposal will establish one of the largest prospective investigations of neurocognitive outcomes in pediatric ALL patients. The research experience gained during the course of this study complements the proposed career development goals. Specifically, didactic training and interaction with experienced mentors in molecular epidemiology (Dr. Scheurer), symptoms research (Dr. Hockenberry), metabolomics (Dr. Devaraj), and neuropsychology (Dr. Ris) will enhance Dr. Brown’s: 1) Content area expertise in patient-reported symptoms and neurocognitive evaluation; 2) Understanding of metabolomics research methods; and 3) Proficiency in grant and scientific writing. The comprehensive career development and research plan outlined in this proposal will address key gaps in Dr. Brown’s training, provide additional research experience, and serve as a unique resource of preliminary data to support future research endeavors.

项目摘要/摘要 该K07职业发展奖提案详细详细介绍了严格的培训，研究和精明计划 这将为布朗博士开展成功的独立研究职业提供基础。布朗博士 长期职业目标是建立一个独立研究计划，重点是 识别新型的生物标志物和可修改的治疗靶标，以减少与治疗相关的燃烧 小儿癌患者的毒性。因此，该提议的研究目标是提早表征 化学疗法相关的神经认知障碍的表型，代谢组和基因组生物标志物 小儿急性淋巴细胞白血病（所有）患者。虽然改善了小儿的治疗方案 导致生存率超过90％，几乎一半的患者经历了慢性治疗 神经认知功能障碍。该提议探讨了中枢神经系统指导所有的假设 化学疗法破坏了脑脊髓液（CSF）代谢组的等效物，表现为急性 症状毒性和长期神经认知功能障碍。因为遗传因素可能控制CSF 代谢组对治疗的反应，我们进一步假设整合遗传和代谢组学数据将 导致发现因果遗传途径。该提案的具体研究目的将评估 是否：1）在所有疗法的诱导后诱导阶段症状毒性反映了化学疗法的指导 神经系统损害，并成为处理后神经认知表现的早期标记； 2）全部 化学疗法诱导涉及正常的CSF代谢组途径的一致和可识别的变化 神经认知功能和发展； 3）遗传变异改变了个人对 神经认知障碍。利用两项具有丰富表型数据和生物测试的NIH资助的研究 存储库，该创新提案将建立 儿科所有患者的神经认知结果。在此过程中获得的研究经验 研究完成了拟议的职业发展目标。具体而言，教学训练和与 经验丰富的分子流行病学导师（Scheurer博士），症状研究（Hockenberry博士）， 代谢组学（Devaraj博士）和神经心理学（RIS博士）将增强Brown博士：1）内容领域 在患者报告的符号和神经认知评估方面的专业知识； 2）了解代谢组学 研究方法； 3）精通赠款和科学写作。全面的职业发展 该提案中概述的研究计划将解决布朗博士培训中的关键差距，提供其他 研究经验，并作为初步数据的独特资源，以支持未来的研究努力。

项目成果

Cerebrospinal Fluid Metabolomic Profiles Associated With Fatigue During Treatment for Pediatric Acute Lymphoblastic Leukemia.

• DOI: 10.1016/j.jpainsymman.2020.08.030
• 发表时间: 2021-03
• 期刊: Journal of pain and symptom management
• 影响因子: 4.7
• 作者: Brown AL;Sok P;Taylor O;Woodhouse JP;Bernhardt MB;Raghubar KP;Kahalley LS;Lupo PJ;Hockenberry MJ;Scheurer ME
• 通讯作者: Scheurer ME

Comparison of the blood, bone marrow, and cerebrospinal fluid metabolomes in children with b-cell acute lymphoblastic leukemia.

• DOI: 10.1038/s41598-021-99147-6
• 发表时间: 2021-10-04
• 期刊: Scientific reports
• 影响因子: 4.6
• 作者: Schraw JM;Woodhouse JP;Bernhardt MB;Taylor OA;Horton TM;Scheurer ME;Okcu MF;Rabin KR;Lupo PJ;Brown AL
• 通讯作者: Brown AL

Utilization of archived neonatal dried blood spots for genome-wide genotyping.

利用存档的新生儿干血斑进行全基因组基因分型。

• DOI: 10.1371/journal.pone.0229352
• 发表时间: 2020
• 期刊: PloS one
• 影响因子: 3.7
• 作者: Sok,Pagna;Lupo,PhilipJ;Richard,MelissaA;Rabin,KarenR;Ehli,ErikA;Kallsen,NoahA;Davies,GarethE;Scheurer,MichaelE;Brown,AustinL
• 通讯作者: Brown,AustinL

A Role for Genetics in Racial Disparities of Therapy-Related Cardiomyopathy.

遗传学在治疗相关心肌病种族差异中的作用。

• DOI: 10.1158/0008-5472.can-21-0137
• 发表时间: 2021
• 期刊: Cancer research
• 影响因子: 11.2
• 作者: Brown,AustinL;Richard,MelissaA
• 通讯作者: Richard,MelissaA

Comparison of hypothyroidism, growth hormone deficiency, and adrenal insufficiency following proton and photon radiotherapy in children with medulloblastoma.

• DOI: 10.1007/s11060-021-03847-y
• 发表时间: 2021-10
• 期刊: Journal of neuro-oncology
• 影响因子: 3.9
• 作者: Aldrich KD;Horne VE;Bielamowicz K;Sonabend RY;Scheurer ME;Paulino AC;Mahajan A;Chintagumpala M;Okcu MF;Brown AL
• 通讯作者: Brown AL